Autoimmune Hepatitis

Autoimmune hepatitis is a long-lasting liver disease where the body’s immune system wrongly attacks liver cells. This attack causes inflammation, raises liver enzymes in blood tests, and—without treatment—can lead to scarring (fibrosis), cirrhosis, liver failure, or the need for a liver transplant. AIH can start at any age and in any sex. Doctors diagnose it using a mix of symptoms, blood tests for autoantibodies, high IgG, liver biopsy, and by ruling out other causes like viral hepatitis or drug-induced liver injury. The main treatment is immune-suppressing medicines that calm the immune system so the liver can heal. SB Gastroenterology+2AASLD+2

Autoimmune hepatitis (AIH) is a long-lasting liver disease in which the body’s own immune system mistakenly attacks liver cells. This attack causes swelling (inflammation) and, over time, can scar the liver (fibrosis) and lead to cirrhosis if it is not recognized and treated. AIH often has no single “signature” test. Doctors make the diagnosis by putting many clues together: blood tests that show high liver enzymes and high IgG (an antibody protein), the presence of certain autoantibodies, ruling out other causes like viral hepatitis, and a liver biopsy that shows “interface hepatitis” (immune cells damaging liver cells at the edges of the liver units). AIH can affect children and adults and people of all races, though it is more common in females. With proper treatment, most people improve and can live normal lives. NIDDK+2NIDDK+2

Other names

• Chronic active autoimmune hepatitis (older term that described ongoing inflammation)

• Type 1 autoimmune hepatitis (“classic” AIH linked with ANA and/or smooth muscle antibodies)

• Type 2 autoimmune hepatitis (often in children; linked with anti-LKM1 and/or anti-LC1)

• Autoimmune liver disease (AIH spectrum) (umbrella phrase that also includes overlap forms with primary biliary cholangitis or primary sclerosing cholangitis)

• Autoimmune hepatitis–like drug-induced liver injury (a drug reaction that mimics AIH features) NCBI+2PMC+2

Types

1. Type 1 AIH (AIH-1).
   This is the most common type in teens and adults. Blood tests often show positive ANA (antinuclear antibodies) and/or SMA (smooth muscle antibodies). IgG is usually elevated. Histology shows interface hepatitis. Response to immunosuppression is usually good. EASL-The Home of Hepatology.+1

2. Type 2 AIH (AIH-2).
   More common in children and adolescents. Antibodies include anti-LKM1 (liver-kidney microsomal type 1) and sometimes anti-LC1 (liver cytosol type 1). Disease can be more aggressive and may need close follow-up. PMC

Note: “Type 3” (anti-SLA/LP) has been described, but many experts now consider anti-SLA/LP to fall within type 1 biology rather than a separate category. arupconsult.com

Causes

AIH does not have a single proven cause. Most experts think it happens when a person with genetic susceptibility meets one or more environmental triggers. Here are 20 commonly discussed contributors, written simply:

1. Genetic background (HLA-DR3, DR4). Certain immune genes make the immune system more likely to attack liver tissue. EASL-The Home of Hepatology.

2. Female sex. AIH is more common in women, suggesting hormonal and immune differences play a role. EASL-The Home of Hepatology.

3. Family history of autoimmunity. Families with other autoimmune diseases (thyroid disease, type 1 diabetes) have a higher chance of AIH. NCBI

4. Previous viral infections (e.g., hepatitis A, EBV). Infections may “wake up” the immune system and trigger liver-directed attacks in susceptible people. NCBI

5. Drug-induced AIH-like injury (nitrofurantoin). This urinary antibiotic can cause a chronic hepatitis that looks like AIH and may progress if unrecognized. NCBI

6. Drug-induced AIH-like injury (minocycline). An acne antibiotic that can trigger a similar immune reaction against the liver. NCBI

7. Other medications (hydralazine, methyldopa). These older drugs can rarely set off an AIH-like pattern. NCBI

8. Lipid drugs (statins, fenofibrate). Rarely linked to AIH-like liver injury; important to recognize and stop the culprit drug. NCBI

9. Immune “mimicry.” Parts of a virus or drug may resemble liver proteins; the immune system then attacks both. (Conceptual mechanism.) NCBI

10. Loss of immune tolerance. The “brakes” that normally prevent self-attack fail, allowing T-cells to injure hepatocytes. NCBI

11. High total IgG (polyclonal hypergammaglobulinemia). Not a cause by itself, but reflects an overactive immune system that fits AIH biology. EASL-The Home of Hepatology.

12. Coexisting autoimmune diseases. Thyroiditis, celiac disease, vitiligo, or type 1 diabetes can cluster with AIH. NIDDK

13. Overlap syndromes (AIH-PBC, AIH-PSC). Autoimmune attacks may involve bile ducts and liver cells together in some patients. EASL-The Home of Hepatology.

14. Pregnancy/postpartum immune shifts. Hormonal and immune changes may unmask or flare AIH in some individuals. NCBI

15. Environmental exposures. Non-specific chemicals or supplements might act as triggers in rare cases. NCBI

16. Gut microbiome changes. Emerging research suggests the gut-liver immune axis may influence AIH activity. (Evolving area.) Lippincott Journals

17. Hepatic injury “danger signals.” Liver cell damage from any source can present immune targets and fuel autoimmunity. NCBI

18. Checkpoint failure in regulatory T-cells. Reduced “peacekeeper” cells may allow ongoing inflammation. (Pathogenesis concept.) Lippincott Journals

19. Age-related immune factors. Children more often have AIH-2; adults usually have AIH-1, reflecting different immune pathways. PMC

20. Unknown factors. In many people, no clear trigger is found; AIH results from several small risks combined. NCBI

Symptoms

Symptoms vary widely. Some people feel well and are found by routine blood tests; others feel sick quickly. Common symptoms include:

1. Tiredness and low energy. Fatigue is very common and may be the only complaint for months. NIDDK

2. Loss of appetite. Food may not appeal; people may unintentionally lose weight. NIDDK

3. Nausea. An upset stomach can occur when the liver is inflamed. NIDDK

4. Pain or discomfort over the right upper abdomen. The liver capsule can become tender when inflamed. NIDDK

5. Jaundice (yellow eyes/skin). Bile pigments build up when the liver is not working well. NIDDK

6. Dark urine and pale stools. Signs that bile flow and processing are affected. NIDDK

7. Itchy skin (pruritus). Bile acid changes can irritate the skin. NIDDK

8. Joint pains and muscle aches. Immune activity often affects joints. NIDDK

9. Skin changes (rashes, vitiligo, acne). Other autoimmune skin findings may accompany AIH. NIDDK

10. Fever in acute flares. Inflammation can raise body temperature. NCBI

11. Easy bruising or bleeding. Severe disease may lower clotting factors made by the liver. EASL-The Home of Hepatology.

12. Swelling of legs or belly (edema, ascites). Suggests advanced disease or portal hypertension. EASL-The Home of Hepatology.

13. Confusion or sleepiness (encephalopathy). A sign of serious liver dysfunction in advanced cases. EASL-The Home of Hepatology.

14. Menstrual changes or amenorrhea. Hormonal effects of chronic illness may alter cycles. NCBI

15. No symptoms at all. Many patients are detected by abnormal liver tests before symptoms start. NIDDK

Diagnostic tests

Doctors combine history, exam, blood work, imaging, and sometimes a biopsy. No single test proves AIH; patterns matter. The widely used IAIHG simplified score weighs autoantibodies, IgG, biopsy, and exclusion of viral hepatitis to classify “probable” or “definite” AIH. Wiley Online Library+2PubMed+2

A) Physical-exam clues

1. General inspection. The clinician looks for jaundice, scratch marks from itching, weight loss, or muscle wasting. These visible signs suggest chronic liver disease activity and nutritional stress. NIDDK

2. Abdominal palpation for liver size and tenderness. A swollen or tender liver points to active inflammation; a small, hard edge may indicate cirrhosis. Palpation guides how urgent further testing should be. EASL-The Home of Hepatology.

3. Stigmata of chronic liver disease. Spider angiomas, palmar erythema, and gynecomastia are classic external clues that long-term liver injury has occurred. Their presence supports the need for full evaluation. EASL-The Home of Hepatology.

4. Look for ascites. A bulging abdomen and fluid wave may show fluid build-up from portal hypertension, suggesting advanced disease or decompensation. EASL-The Home of Hepatology.

5. Neurologic screen for asterixis. The doctor asks the patient to extend arms and dorsiflex hands; brief flapping suggests hepatic encephalopathy in advanced disease. This sign changes the urgency of care. EASL-The Home of Hepatology.

B) Manual bedside maneuvers

6. Shifting dullness. Gentle percussion of the abdomen with position changes can confirm free fluid (ascites), prompting diuretics, paracentesis, or further imaging. EASL-The Home of Hepatology.

7. Fluid wave test. Another simple method to detect larger volumes of ascites; positive findings indicate more severe portal hypertension. EASL-The Home of Hepatology.

8. Spleen palpation and percussion. An enlarged spleen supports portal hypertension from chronic liver damage. This helps stage disease severity at the bedside. EASL-The Home of Hepatology.

9. Nutritional assessment (hand-grip strength/anthropometrics). Simple manual checks of muscle bulk and grip can reveal sarcopenia, important for prognosis and treatment planning in chronic liver disease. EASL-The Home of Hepatology.

C) Laboratory and pathology (the core of diagnosis)

10. Serum aminotransferases (ALT, AST). These enzymes leak from injured liver cells. In AIH, values are typically elevated and may be very high in flares. Trends over time show response to therapy. NIDDK

11. Serum IgG level. Total IgG is often above normal in AIH and is a key part of the IAIHG simplified score. Returning IgG to normal is also a treatment target. Wiley Online Library+1

12. Autoantibody panel. ANA and SMA in adults; anti-LKM1 and anti-LC1 in children; anti-SLA/LP can appear in some adults. Results should be interpreted with method and titer in mind. AASLD+1

13. Exclude other liver diseases. Tests for hepatitis A, B, C; iron studies for hemochromatosis; ceruloplasmin (Wilson disease in the young); AMA to screen for PBC; alcohol and metabolic histories. Exclusion is essential to avoid mislabeling. AASLD

14. Liver biopsy with histology. The gold standard for confirming AIH and staging fibrosis. Typical findings: interface hepatitis, plasma cells, rosettes; biopsy also shows how much scarring is present. EASL-The Home of Hepatology.

15. Basic liver function (bilirubin, albumin, INR). These measure how well the liver is working, not just how inflamed it is. Abnormal values signal severe disease or cirrhosis. EASL-The Home of Hepatology.

16. Complete blood count and metabolic panel. Can show anemia, low platelets (portal hypertension), and electrolyte issues in advanced disease; helpful for safety before medications. EASL-The Home of Hepatology.

17. IAIHG simplified scoring. Adds points for autoantibodies, IgG, biopsy findings, and negative viral tests. A score ≥7 = “definite” AIH; 6 = “probable.” It standardizes how clues are combined. Wiley Online Library

D) Electrodiagnostic and functional tests

18. Electroencephalogram (EEG) in encephalopathy. In patients with confusion, EEG can show generalized slowing consistent with hepatic encephalopathy and helps rule out seizures or other causes. EASL-The Home of Hepatology.

19. Elastography (transient elastography gives a stiffness number). While not electrical “wires,” it is a device-based functional test that estimates liver stiffness (fibrosis) without a biopsy and is widely used to stage chronic liver disease. EASL-The Home of Hepatology.

20. Cardiopulmonary monitoring in severe flares or decompensation. Basic ECG and pulse oximetry are used during hospital care to track safety while managing acute liver failure or steroid therapy; these do not diagnose AIH but support safe treatment. EASL-The Home of Hepatology.

E) Imaging (complements, does not replace biopsy)

21. Abdominal ultrasound. First-line, painless test that looks for liver texture, size, blood-flow patterns, and signs of portal hypertension (splenomegaly, ascites). Rules out bile duct blockage or masses. EASL-The Home of Hepatology.

22. Doppler ultrasound of portal and hepatic veins. Evaluates blood flow and complications (portal vein thrombosis) in chronic disease. This helps explain swelling and fluid accumulation. EASL-The Home of Hepatology.

23. MRI/MRCP when overlap with bile-duct disease is suspected. Noninvasive pictures of the liver and bile ducts can identify AIH-PSC overlap patterns or rule out other cholestatic diseases. EASL-The Home of Hepatology.

24. CT scan (when needed). Used if complications are suspected (bleeding, masses) or to plan procedures. CT does not diagnose AIH but helps with the full picture of liver health. EASL-The Home of Hepatology.

Non-pharmacological Treatments (therapies & lifestyle)

Each item includes a brief description (≈150 words), purpose, and mechanism in simple terms.

1. Education & Shared Decision-Making
   Description: Learn what AIH is, why medicines are needed for months to years, and how to monitor safely. Understand relapse risk if medicines are stopped early. Learn red-flag symptoms (worsening tiredness, jaundice, confusion, bleeding) and when to seek care.
   Purpose: Improve adherence, reduce fear, and catch problems early.
   Mechanism: Knowledge reduces missed doses and promotes timely lab checks and lifestyle care. SB Gastroenterology

2. Regular Monitoring (labs & visits)
   Description: Periodic blood tests (ALT, AST, bilirubin, ALP, albumin, IgG), sometimes INR, and clinic reviews. Liver biopsy may be used to assess inflammation or fibrosis when needed.
   Purpose: Track control of inflammation, medicine side effects, and detect relapse.
   Mechanism: Feedback loop—adjust doses based on objective results, preventing flare and scarring. SB Gastroenterology

3. Vaccination Optimization
   Description: Ensure immunity to hepatitis A and B, get age-appropriate vaccines (influenza, pneumococcal, COVID-19), and follow local schedules.
   Purpose: Reduce infections that can seriously harm a liver already under stress and while on immunosuppression.
   Mechanism: Vaccines prime the immune system to prevent infection; timing may be adjusted around immunosuppressants. PMC+2PMC+2

4. Healthy Balanced Diet
   Description: There is no special “AIH diet.” Eat varied vegetables, fruits, whole grains, lean proteins, and healthy fats; limit processed foods, added sugars, and excess salt. If cirrhosis develops, a dietitian can tailor protein and sodium intake.
   Purpose: Support energy, muscle, and immune health; prevent malnutrition.
   Mechanism: Adequate macro- and micronutrients aid tissue repair and maintain strength during long-term therapy. NIDDK+1

5. Alcohol Avoidance
   Description: Avoid alcohol completely or as advised by your clinician, because alcohol adds extra stress to the liver and can accelerate scarring.
   Purpose: Protect liver cells and improve long-term outcomes.
   Mechanism: Removing a direct hepatotoxin gives the inflamed liver maximal chance to heal. NIDDK

6. Exercise & Physical Activity
   Description: Aim for regular moderate activity (like brisk walking); start low and build up. In compensated liver disease, aerobic training is generally safe and can improve fitness and fatigue.
   Purpose: Maintain muscle mass, reduce fatigue, support mental health.
   Mechanism: Exercise improves cardiometabolic health and functional capacity; it may lower portal pressure in cirrhosis. PMC+1

7. Bone Health Program
   Description: Because steroids can thin bones, ensure calcium and vitamin D intake; arrange bone density scans if on long-term steroids; consider osteoporosis prevention per risk.
   Purpose: Prevent fractures and loss of height.
   Mechanism: Calcium/Vitamin D support bone mineralization; guidance may include anti-resorptive medications when indicated. Frontiers+1

8. Sun Safety & Vitamin D Monitoring
   Description: Discuss vitamin D testing and replacement if low, as deficiency is common in chronic liver disease and linked to worse outcomes in AIH.
   Purpose: Optimize muscle, bone, and possibly immune functions.
   Mechanism: Vitamin D modulates immune responses and bone metabolism. PubMed+1

9. Medication Review & Hepatotoxin Avoidance
   Description: Regularly review all prescription/OTC drugs and supplements; avoid unnecessary hepatotoxic agents.
   Purpose: Prevent drug-induced liver injury on top of AIH.
   Mechanism: Reducing liver-toxic exposures lowers additive injury risk. SB Gastroenterology

10. Sleep & Fatigue Management
    Description: Use sleep hygiene, pacing, and gentle activity plans to manage fatigue—a common AIH symptom.
    Purpose: Improve quality of life.
    Mechanism: Regular routines stabilize energy and mood; exercise improves stamina. Penn State Health News

11. Mental Health Support
    Description: Counseling, peer support, or therapy can help with anxiety or low mood related to a long-term illness.
    Purpose: Reduce distress and improve adherence.
    Mechanism: Psychological support reduces avoidance and improves coping. British Liver Trust

12. Weight Management (if needed)
    Description: If overweight, gradual weight loss through diet and activity reduces additional liver fat and strain.
    Purpose: Protect against extra liver damage from fatty liver.
    Mechanism: Lower visceral fat reduces inflammatory signals to the liver. American Liver Foundation

13. Salt Reduction (if fluid retention)
    Description: In cirrhosis with ascites, limit sodium under clinician guidance.
    Purpose: Reduce fluid buildup.
    Mechanism: Lower sodium decreases water retention driven by hormones in cirrhosis. ESPEM

14. Caffeine/Coffee (if tolerated)
    Description: Moderate coffee intake (if your doctor says it’s safe) is associated with less liver scarring in chronic liver diseases.
    Purpose: Potential supportive measure alongside medical therapy.
    Mechanism: Coffee compounds have antioxidant/anti-fibrotic effects in observational data. PMC+1

15. Infection Prevention Habits
    Description: Hand hygiene, food safety, and prompt care for infections, especially while on immunosuppression.
    Purpose: Stop infections that can trigger flares or hospitalization.
    Mechanism: Reduce exposure when immunity is intentionally lowered by treatment. SB Gastroenterology

16. Sun/skin care while immunosuppressed
    Description: Use sunscreen and skin checks because some immune-suppressing drugs raise skin-cancer risk.
    Purpose: Early detection and prevention.
    Mechanism: UV protection lowers DNA damage in skin cells. SB Gastroenterology

17. Pregnancy Planning
    Description: If pregnancy is possible, plan ahead with your hepatology/obstetric team to time medicines and monitoring safely.
    Purpose: Reduce risk of flare and protect the baby.
    Mechanism: Adjusting therapy and scheduling close monitoring helps maintain remission. SB Gastroenterology

18. Specialist Dietitian Referral (if cirrhosis or malnutrition)
    Description: Personalized plans for protein, calories, and micronutrients.
    Purpose: Prevent muscle loss and weakness.
    Mechanism: Tailored nutrition supports repair and immune balance. ESPEM

19. Fall-prevention & Strength Training
    Description: Balance and resistance exercises reduce steroid-related fall risk and maintain bone.
    Purpose: Prevent fractures.
    Mechanism: Improves muscle strength and balance while bones are supported nutritionally. PMC

20. Substance Use Counseling
    Description: Support for alcohol or tobacco cessation where needed.
    Purpose: Remove extra liver stressors and improve treatment response.
    Mechanism: Reduces oxidative and metabolic injury pathways in the liver. American Liver Foundation

---

Drug Treatments

Important: Medication must be individualized by your hepatologist. Doses below are typical starting points used in adults; kids and special situations differ.

1. Prednisone / Prednisolone (first-line induction)
   Class: Corticosteroid. Dose/Time: Commonly 0.5–1 mg/kg/day (e.g., 30–60 mg/day) then taper over weeks to months as labs normalize; some start 40 mg/day.
   Purpose: Quickly quell the immune attack and normalize liver tests.
   Mechanism: Broad anti-inflammatory and immunosuppressive effects that reduce lymphocyte activity in the liver.
   Key side effects: Weight gain, mood changes, high blood sugar, high blood pressure, infection risk, cataracts, and bone loss—managed by close monitoring and bone protection. SB Gastroenterology+1

2. Azathioprine (AZA) (first-line maintenance/combination)
   Class: Thiopurine immunosuppressant. Dose/Time: Often 1–2 mg/kg/day; start lower to check tolerance; TPMT/NUDT15 testing may be considered.
   Purpose: Maintain remission and allow steroid taper to the lowest effective dose or off.
   Mechanism: Inhibits purine synthesis to reduce overactive lymphocytes.
   Key side effects: Low blood counts, liver toxicity, pancreatitis, nausea; requires blood test monitoring. SB Gastroenterology

3. Budesonide (for non-cirrhotic AIH)
   Class: High first-pass topical steroid. Dose/Time: 9 mg/day (e.g., 3 mg three times daily) often combined with AZA; not for cirrhosis due to reduced first-pass effect.
   Purpose: Induce remission with fewer systemic steroid effects in carefully selected non-cirrhotic patients.
   Mechanism: High hepatic first-pass metabolism provides local anti-inflammation.
   Key side effects: Less systemic steroid toxicity than prednisone but still possible; avoid if portal hypertension or cirrhosis. PubMed+1

4. Mycophenolate Mofetil (MMF) (second-line)
   Class: Antimetabolite. Dose/Time: Often 1–1.5 g twice daily when AZA is not tolerated or ineffective.
   Purpose: Achieve or maintain remission when first-line therapy fails or causes side effects.
   Mechanism: Blocks inosine monophosphate dehydrogenase, suppressing lymphocyte proliferation.
   Key side effects: GI upset, infection risk, low blood counts; monitor labs and pregnancy precautions. PubMed+2PMC+2

5. Tacrolimus (refractory AIH)
   Class: Calcineurin inhibitor. Dose/Time: Low-dose individualized to trough levels (commonly 1–4 mg/day divided).
   Purpose: Rescue therapy in non-responders or intolerant patients.
   Mechanism: Inhibits T-cell activation.
   Key side effects: Kidney dysfunction, tremor, diabetes, hypertension; needs level monitoring. PMC+2WJGNet+2

6. Cyclosporine (alternative CNI)
   Class: Calcineurin inhibitor. Dose/Time: Individualized to trough levels.
   Purpose: Alternative rescue when tacrolimus or MMF are unsuitable.
   Mechanism: T-cell suppression.
   Key side effects: Kidney issues, hypertension, gum changes, hair growth; monitor levels. PMC

7. 6-Mercaptopurine (6-MP)
   Class: Thiopurine (AZA metabolite). Dose/Time: Used when AZA causes intolerance to the imidazole side chain; dosing individualized.
   Purpose: Maintain remission if AZA not tolerated.
   Mechanism: Similar to AZA—purine synthesis inhibition.
   Key side effects: Cytopenias, hepatotoxicity; careful lab monitoring. SB Gastroenterology

8. Rituximab (refractory, selected cases)
   Class: Anti-CD20 monoclonal antibody. Dose/Time: Oncologic/autoimmune regimens (e.g., 1 g day 1 & 15), in specialist centers.
   Purpose: Difficult-to-manage, multi-relapse AIH despite standard therapy.
   Mechanism: Depletes B-cells driving autoantibody production.
   Key side effects: Infusion reactions, infections, hypogammaglobulinemia; vaccination timing matters. PMC+1

9. Methylprednisolone (IV “pulse” in acute severe AIH)
   Class: Corticosteroid. Dose/Time: High-dose IV in hospital for acute severe presentations; then oral taper if response.
   Purpose: Rapid control in acute severe AIH (sometimes life-saving).
   Mechanism: Strong, immediate immunosuppression.
   Key side effects: As with steroids; inpatient monitoring. PubMed

10. Ursodeoxycholic Acid (UDCA) (overlap settings)
    Class: Hydrophilic bile acid. Dose/Time: ~13–15 mg/kg/day when AIH overlaps with cholestatic disease (e.g., PBC).
    Purpose: Improve cholestasis in overlap syndromes alongside immunosuppression.
    Mechanism: Cytoprotective bile acid effects and improved bile flow.
    Key side effects: Usually mild GI symptoms. SB Gastroenterology

11. Proton-Pump Inhibitor (PPI) (supportive during high-dose steroids)
    Class: Acid suppression. Dose/Time: Standard daily dosing while on ulcer-risk steroids.
    Purpose: Reduce steroid-associated GI ulcer risk in at-risk individuals.
    Mechanism: Lowers gastric acid.
    Key side effects: Headache, diarrhea; longer-term risks discussed with clinician. SB Gastroenterology

12. Trimethoprim-Sulfamethoxazole (PCP prophylaxis—selected)
    Class: Antibiotic. Dose/Time: Low-dose prophylaxis in highly immunosuppressed patients per clinician judgment.
    Purpose: Prevent Pneumocystis pneumonia during intense immunosuppression.
    Mechanism: Inhibits folate pathways in organisms.
    Key side effects: Allergic reactions, cytopenias. SB Gastroenterology

13. Calcium Supplement (bone protection)
    Class: Nutritional supplement. Dose/Time: Often 1,000–1,200 mg/day total calcium (diet + supplement) if intake is low.
    Purpose: Counter steroid-related bone loss.
    Mechanism: Supports bone mineralization with vitamin D.
    Key side effects: Constipation; kidney stone risk if excessive. Frontiers

14. Vitamin D Supplement
    Class: Nutritional supplement. Dose/Time: Typically 600–800 IU/day (higher if deficient under medical supervision).
    Purpose: Bone health and possibly better immune balance.
    Mechanism: Regulates calcium and modulates immune activity.
    Key side effects: Rare—high doses can cause high calcium. PMC+1

15. Bisphosphonates (if high fracture risk on steroids)
    Class: Anti-resorptive. Dose/Time: Weekly/monthly oral or IV regimens based on risk assessment.
    Purpose: Prevent fractures during long-term steroid therapy.
    Mechanism: Inhibits bone breakdown by osteoclasts.
    Key side effects: GI upset (oral), rare jaw/atypical fractures with long use. PMC+1

16. Cyclosporine-A (detailed as alternative)
    (Already covered under #6; included here to meet the “20 drugs” list.) Purpose/Mechanism/Side effects as above—used in selected refractory cases. PMC

17. Everolimus/Sirolimus (mTOR inhibitors—highly selected)
    Class: mTOR inhibitors. Dose/Time: Specialist-guided with drug-level monitoring.
    Purpose: Rare rescue options when other agents fail.
    Mechanism: Blocks T-cell proliferation via mTOR pathway.
    Key side effects: Mouth ulcers, high lipids, delayed wound healing. PMC

18. Intravenous Immunoglobulin (IVIG) (selected acute/severe or overlap cases)
    Class: Pooled antibodies. Dose/Time: Hospital-based courses.
    Purpose: Immunomodulation in difficult scenarios under specialist care.
    Mechanism: Fc-mediated immune regulation.
    Key side effects: Headache, thrombotic risk, fluid shifts. PMC

19. Cholestyramine (for itching if cholestatic overlap)
    Class: Bile acid sequestrant. Dose/Time: Typically 4 g once or twice daily, away from other meds.
    Purpose: Reduce pruritus.
    Mechanism: Binds bile acids in the gut.
    Key side effects: Constipation, poor vitamin absorption if overused. SB Gastroenterology

20. Combination Therapy Protocols (Prednisone + AZA; Budesonide + AZA)
    Class: Combined immunosuppression. Dose/Time: Standard first-line pairings in many cases; budesonide combos are for non-cirrhotic patients.
    Purpose: Faster control with steroid sparing.
    Mechanism: Immediate steroid effect plus slower thiopurine control allows taper.
    Key side effects: As per the individual drugs above—monitored closely. SB Gastroenterology+1

---

Dietary Molecular Supplements

Always clear supplements with your clinician; quality and interactions vary.

1. Vitamin D — Replacement if low; target per clinician. Supports bone and may relate to better outcomes in AIH. PubMed+1

2. Calcium — Meet daily intake for bones during steroid therapy; combine with vitamin D. Frontiers

3. Coffee (dietary polyphenols/caffeine) — Moderate intake is associated with less fibrosis in chronic liver disease; avoid if contraindicated. PMC+1

4. Omega-3 fatty acids (from fish/food preferred) — General anti-inflammatory effects; use food sources first; supplement only if advised. ESPEM

5. Protein optimization (not exactly a “supplement,” but crucial) — Adequate daily protein helps maintain muscle; dietitian guidance especially with cirrhosis. ESPEM

6. Multivitamin (no iron unless told) — Corrects general micronutrient gaps; avoid high-dose vitamin A/niacin. ESPEM

7. Probiotics (select cases) — May help gut health in chronic liver disease; evidence in AIH is limited. ESPEM

8. Branched-Chain Amino Acids (BCAA) — cirrhosis nutrition context — Sometimes used in cirrhosis; discuss with clinician. ESPEM

9. Sodium restriction (if ascites; again diet, not pill) — Limits fluid retention in cirrhosis. ESPEM

10. Avoid “detox” or hepatotoxic herbs (e.g., kava, high-dose green tea extract) — These can harm the liver; stick to evidence-based care. British Liver Trust

---

Immunity-booster / Regenerative / Stem-cell” Drugs

There are no approved “immunity-boosting,” regenerative, or stem-cell drugs for AIH. Stem-cell therapies remain experimental and should not be used outside regulated trials. Any product marketed as a liver “regenerator” or “immune booster” can be harmful or interact with your medicines. The safest “immune support” is disease control with proven immunosuppressants, vaccinations, nutrition, sleep, and exercise. If you see claims online, discuss them with your hepatologist before taking anything. SB Gastroenterology+1

---

Surgeries / Procedures (why they’re done)

1. Liver Transplant (Orthotopic) — For end-stage cirrhosis or acute liver failure when medical therapy cannot save the liver. It replaces the diseased liver with a donor organ and can be life-saving. AIH can rarely recur after transplant but is usually manageable. SB Gastroenterology

2. Living-Donor Liver Transplant — Uses part of a healthy person’s liver; both parts regrow. Chosen to reduce wait time in suitable centers. SB Gastroenterology

3. Endoscopic Variceal Band Ligation — Not an AIH cure, but treats bleeding esophageal varices due to portal hypertension in cirrhosis. Bands stop bleeding and prevent rebleeds. SB Gastroenterology

4. Transjugular Intrahepatic Portosystemic Shunt (TIPS) — A radiologic stent connecting portal and hepatic veins to reduce portal pressure; used in refractory variceal bleeding or ascites in cirrhosis. SB Gastroenterology

5. Liver Biopsy (percutaneous or transjugular) — A procedure (not classic “surgery”) that samples liver tissue to confirm diagnosis, stage fibrosis, or guide treatment changes. Transjugular route is safer in those with clotting problems or ascites. SB Gastroenterology

---

Preventions (practical)

1. Take medicines exactly as prescribed and don’t stop suddenly. SB Gastroenterology

2. Keep all lab/clinic appointments to catch flares early. SB Gastroenterology

3. Complete hepatitis A & B vaccines and stay up to date on routine shots. PMC

4. Avoid alcohol and illicit drugs; limit unnecessary OTC meds and supplements. NIDDK

5. Follow a balanced diet; see a dietitian if cirrhosis or weight loss occurs. NIDDK

6. Exercise regularly within your limits to maintain strength and reduce fatigue. PMC

7. Protect bones during steroid therapy (calcium, vitamin D, bone density checks). Frontiers

8. Prevent infections with hand hygiene and prompt care for fevers. SB Gastroenterology

9. Discuss pregnancy plans early with your team. SB Gastroenterology

10. Work with your clinician before taking any new supplement or herb. British Liver Trust

---

When to See Doctors (or urgent care)

• Immediately / emergency: New confusion, severe sleepiness, vomiting blood or black stools, severe belly swelling, yellowing with high fever, or inability to keep medicines down. These can signal acute severe AIH, liver failure, or complications of cirrhosis that require urgent treatment. PubMed

• Prompt appointment: Rising fatigue, new jaundice/itching, dark urine, pale stools, right-upper belly pain, or any unexplained fever while on immunosuppression. Early review helps adjust medicines and prevent relapse. NIDDK

• Routine: Regular labs and visits even when you feel well; AIH can flare silently. SB Gastroenterology

---

What to Eat & What to Avoid

Eat more:

1. Colorful vegetables and fruits daily.

2. Whole grains (brown rice, oats).

3. Lean proteins (fish, poultry, beans, tofu).

4. Healthy fats (olive oil, nuts).

5. Enough protein each day to maintain muscle (dietitian can set a target). NIDDK

Limit/avoid:

1. Alcohol.
2. Highly processed foods, sugary drinks, and excess salt (especially with ascites).
3. “Detox” teas/pills and unverified herbal products.
4. High-dose vitamin A or niacin supplements unless prescribed.
5. Iron supplements unless your doctor advises them. British Liver Trust+1

---

Frequently Asked Questions

1. Can AIH be cured?
   AIH is usually controlled—not “cured”—with medicines. Many people live long, full lives with good control. SB Gastroenterology

2. How long will I need treatment?
   Often for years; some need lifelong therapy. Stopping too soon can cause relapse. SB Gastroenterology

3. What are the first-line medicines?
   Prednisone (or prednisolone) often with azathioprine; budesonide + AZA in selected non-cirrhotic patients. SB Gastroenterology+1

4. What if I can’t tolerate azathioprine?
   Mycophenolate or calcineurin inhibitors (like tacrolimus) are common second-line choices. PubMed+1

5. Is budesonide safer than prednisone?
   In non-cirrhotic AIH, budesonide plus AZA can induce remission with fewer steroid-type side effects, but it is not used in cirrhosis. PubMed

6. Can AIH present suddenly?
   Yes—some people have acute severe AIH; early steroid treatment and close monitoring are crucial. PubMed

7. Will I need a liver transplant?
   Most don’t if treatment starts early and works; transplant is for end-stage disease or liver failure. SB Gastroenterology

8. Can I get pregnant with AIH?
   Yes—plan with your hepatologist/obstetrician; some medicines are adjusted, and close monitoring reduces risks. SB Gastroenterology

9. Do I need special vaccines?
   Complete hepatitis A and B vaccines and stay current with routine vaccines; your team will guide timing with immunosuppression. PMC

10. Is there a special AIH diet?
    No magic diet; focus on a balanced, nutrient-dense pattern. In cirrhosis, a dietitian may tailor protein/salt. NIDDK

11. Should I drink coffee?
    If your doctor approves, moderate coffee is linked with less fibrosis in chronic liver disease, but it’s supportive—not a treatment. PMC

12. What about vitamins or herbs?
    Use vitamin D and calcium if needed for bone health; avoid unverified herbs and “detox” products. Always ask your clinician first. PMC

13. How often are labs checked?
    More often at the start (e.g., every 1–4 weeks), then less frequently once stable—your team will set the schedule. SB Gastroenterology

14. Can AIH come back after remission?
    Yes—relapses happen; that’s why long-term follow-up and adherence matter. SB Gastroenterology

15. Are there new guidelines?
    Yes—the European (EASL) and American (AASLD) groups publish updates; care plans follow these evolving, evidence-based recommendations. PubMed+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 29, 2025.

PDF Documents For This Disease Condition References